Welcome to our dedicated page for Pulmonx Corporation news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx Corporation stock.
Pulmonx Corporation (Nasdaq: LUNG) is a leading medical technology company dedicated to transforming the treatment of severe lung diseases. The company's primary focus is on developing life-changing, minimally invasive technologies to enhance the lives of patients suffering from emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD). Pulmonx's flagship product, the Zephyr Endobronchial Valve (EBV), offers a non-surgical treatment option to reduce the volume of diseased lung tissue, thereby improving breathing and increasing patients' activity levels. This innovative approach provides a viable alternative to lung volume reduction surgery and lung transplantation, which have significant limitations and risks.
Pulmonx also offers the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which work in tandem with the Zephyr Valve to optimize patient selection and treatment outcomes. These technologies are pivotal in managing advanced emphysema and are commercially available in over 25 countries.
In recent financial updates, Pulmonx reported robust growth, with total worldwide revenue reaching $17.2 million in Q2 2023, marking a 23% increase compared to the same period in 2022. U.S. revenue alone saw a 28% rise, highlighting the strong domestic market traction. The company's ongoing commercial success and adoption of Zephyr Valve procedures are driving this growth.
Pulmonx's fiscal health remains strong, with a gross profit of $12.7 million in Q2 2023 and a gross margin of 74%. Operating expenses rose to $29.2 million, mainly due to increased clinical and development costs associated with the AeriSeal program, alongside higher selling, legal, and stock-based compensation expenses. Despite a net loss of $16.2 million for the quarter, the company maintains significant cash reserves, totaling $147.6 million as of June 30, 2023.
Looking ahead, Pulmonx has raised its 2023 revenue guidance to $64-$66 million, reflecting an expected growth rate of 19%-23% over the previous year. Operating expenses for the year are projected to be between $112 million and $114 million. The company remains committed to expanding its global market reach and meeting the substantial unmet clinical needs of patients with severe emphysema.
For investors and stakeholders, Pulmonx represents a dynamic and promising entity in the medtech space, continually striving to enhance patient outcomes through groundbreaking innovations in pulmonary care.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 9, 2023, at 3:55 PM PT / 6:55 PM ET. The presentation will be accessible via a live and archived webcast on the company’s website.
Pulmonx is known for its Zephyr® Endobronchial Valve, which treats patients with severe emphysema/COPD. This device has received FDA pre-market approval as a breakthrough device and is available in over 25 countries. With more than 100,000 valves employed, over 25,000 patients have been treated worldwide.
Pulmonx Corporation (Nasdaq: LUNG) plans to release its financial results for Q1 2023 on Tuesday, May 2, 2023, after trading hours. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Pulmonx is recognized for its innovative treatments for lung diseases, particularly the Zephyr® Endobronchial Valve, which has received FDA pre-market approval as a breakthrough device. The company has successfully deployed over 100,000 valves to treat more than 25,000 patients globally, illustrating its significant market presence and commitment to advancing pulmonary care.
Pulmonx Corporation (LUNG) reported strong financial results for Q4 and full year 2022, achieving a record worldwide revenue of $53.7 million, an 11% increase from 2021. Q4 revenue reached $15.4 million, marking a 13% year-over-year growth. U.S. revenue for 2022 increased by 30% to $32.5 million, while international revenue saw a 10% decline to $21.2 million. The gross margin was stable at 74% for the year. Despite a net loss of $58.9 million in 2022, Pulmonx expects revenue for 2023 to rise to between $63 million and $65 million.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, will participate in a fireside chat at the Citi 2023 Healthcare Conference on March 2, 2023, at 10:15 AM PT / 1:15 PM ET. The event will be accessible via a live and archived webcast on the company’s Investors section of their website.
Pulmonx is known for its Zephyr® Endobronchial Valve and related systems used extensively in treating severe emphysema/COPD, with over 100,000 valves utilized in more than 25,000 patients worldwide.
Pulmonx Corporation (Nasdaq: LUNG) will announce its financial results for Q4 and full year 2022 on February 22, 2023, after market close. The management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The company focuses on minimally invasive treatments for lung diseases, including the Zephyr® Endobronchial Valve, which has been commercially available in over 25 countries and used to treat more than 25,000 patients.
Investors can access a live and archived webcast of the event on the Investors section of the Pulmonx website.
Pulmonx Corporation has partnered with the American Lung Association to enhance education on Endobronchial Valves, a treatment for severe COPD. This initiative focuses on raising awareness among patients and healthcare providers about available treatment options. The campaign aims to empower individuals living with COPD by highlighting the minimally invasive nature of Endobronchial Valves, which can significantly improve quality of life. With over 25,000 patients treated with the Zephyr Valves, this collaboration seeks to expand treatment accessibility and knowledge.
Pulmonx Corporation announced the approval of the Zephyr Endobronchial Valve in Japan for treating severe COPD/emphysema patients. The Japanese Ministry of Health has validated the product following a positive PMDA recommendation, emphasizing significant patient benefits such as improved lung function and quality of life. With over 600,000 Japanese patients suffering from severe COPD, this minimally invasive procedure offers a new alternative to traditional invasive surgeries. Pulmonx aims to collaborate for reimbursement strategies prior to commercialization.
Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on November 30, 2022, at 11:30 AM PT / 2:30 PM ET. A live and archived webcast will be available on the company’s investor website.
Pulmonx is known for its minimally invasive treatments for severe lung diseases, including the Zephyr® Endobronchial Valve, which has been used in over 25,000 patients globally. The Zephyr Valve has gained FDA breakthrough device designation and is available in more than 25 countries.
FAQ
What is the current stock price of Pulmonx Corporation (LUNG)?
What is the market cap of Pulmonx Corporation (LUNG)?
What is Pulmonx Corporation's primary focus?
What products does Pulmonx offer?
How does the Zephyr Endobronchial Valve work?
What recent financial achievements has Pulmonx reported?
What is Pulmonx's financial outlook for 2023?
In which markets are Pulmonx's products commercially available?
What are the key benefits of the Zephyr Valve treatment?
How does Pulmonx support its products' adoption in the medical community?
Who is the current interim CFO of Pulmonx Corporation?
Where can I find more information about Pulmonx Corporation?
